Primary and secondary prevention protocols aim at reducing the plasma levels of lipids-with
particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations–in …

Background. Elevated plasma low‐density lipoprotein cholesterol (LDL‐C) is the main risk
factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the drugs of choice for …

Background The effectiveness of lipid‐lowering therapy (LLT) is affected by both intensity
and adherence. This study evaluated the associations of LLT intensity, adherence, and the …

Abstract Purpose of Review Low-density lipoprotein cholesterol (LDL-C) is the most
important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This article …

Aims Effective statin therapy is a cornerstone of secondary prevention after myocardial
infarction (MI). Real-life statin dosing is nevertheless suboptimal and largely determined …

Background and aims Heterozygous familial hypercholesterolemia (HeFH) is increasingly
better diagnosed and treatments can improve the cardiovascular prognosis. We evaluated …

Background Oral lipid-lowering treatment (LLT) is the standard of care for patients with
cardiovascular disease (CVD). However, insufficient treatment intensity and poor adherence …

Abstract Background The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent
Ethyl–Intervention Trial) trial demonstrated that high-dose icosapent-ethyl reduced the risk of …

Despite the availability of lipid-lowering therapies (LLTs) that are safe and effective, the
overall rate of low-density lipoprotein cholesterol (LDL-C) control at a population level in real …

Background The effectiveness of lipid-lowering therapy (LLT) for primary prevention of
atherosclerotic cardiovascular disease (ASCVD) in routine care may depend on treatment …